Entities / Company
AbbVie.
pharmaceutical company
- Reports this week
- 16
- Active events
- 10
- Connections
- 506
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Active this week
-
Kori Wallace was appointed vice president at AbbVie.Some support2 reports
-
AbbVie presented clinical data at the European Society for Medical Oncology (ESMO) Congress held in Madrid.Some support2 reports
-
Ken Griffin made investment moves on October 18, 2026, buying shares of AbbVie and Abbott Laboratories, and boosting Eli Lilly shares.Some support1 report
-
AbbVie's Humira is losing exclusivity and facing intense competition from Skyrizi and Rinvoq.Some support4 reports
-
AbbVie presented research findings related to Inflammatory Bowel Disease (IBD) at the United European Gastroenterology (UEG) Week conference.Some support2 reports
-
AbbVie products are succeeding Humira in the market, while FDA approvals and Fed caution influence market expectations.Well supported4 reports1 development inside
-
AbbVie overcame the loss of Humira exclusivity, leading to a stock rally while Pfizer stock sank.Some support1 report
-
Financial results and stock performance comparisons among AbbVie, Johnson & Johnson, Eli Lilly, and Merck.Well supported4 reports2 developments inside
-
Johnson & Johnson is co-commercializing the prescription medicine IMBRUVICA with Pharmacyclics, a subsidiary of AbbVie.Some support1 report
-
AbbVie presented abstracts at the American College of Gastroenterology meeting.Some support1 report
Earlier this month
-
A group of major pharmaceutical companies, including AbbVie, Bristol-Myers Squibb, Amgen, Pfizer, Moderna, and Merck, are noted as peers operating in the highly regulated pharmaceutical sector.Some support4 reports1 development inside
-
Major pharmaceutical companies are competing for investment capital.Some support1 report
-
Declining sales of Humira due to biosimilar erosion.Well supported7 reports2 developments inside
-
AbbVie and Eli Lilly are competing in the pharmaceutical market.Well supported7 reports
-
AbbVie, Boehringer Ingelheim, and Pfizer were present at a clinical conference in Las Vegas.Some support1 report
-
AbbVie, Altria, and CVX are being utilized in a dividend ladder investment strategy.Some support2 reports
-
Medicare pricing negotiations are impacting major pharmaceutical companies, including AbbVie, Eli Lilly, and Merck, who are seeking pricing exemptions.Well supported3 reports3 developments inside
-
Jay Korada held senior analytics roles at both AbbVie and Bristol-Myers Squibb.Some support1 report
-
Canandaigua National Trust Co of Florida bought a new stake in AbbVie shares and granted Breakthrough Therapy Designations for one of its drugs.Some support2 reports
-
OpenSecrets tracked donations to Virginia Foxx, who held stocks in AbbVie, in North Carolina.Some support1 report
-
Analysts highlighted bullish calls and raised price targets for AbbVie, Moderna, and Eli Lilly amid sector optimism.Some support1 report
-
AbbVie, Amgen, Micron Technology, and NetApp all showed strength in the stock market on October 7, 2026.Some support1 report
-
AbbVie, Genmab, and Sarah Cannon Research Institute announced the joint development of Epkinly for DLBCL treatment.Well supported7 reports1 development inside
-
A drug application from AbbVie is currently seeking a positive opinion from the CHMP, with the final decision impacting market access in the EU.Some support5 reports
-
MarketBeat's screener has identified a list of dividend stocks.Well supported16 reports1 development inside
-
AbbVie's product portfolio was bolstered by the acquisition of Allergan, while Humira sales faced erosion due to patent loss and biosimilar competition.Some support4 reports1 development inside
-
A tariff plan caused market tanking on August 22, 2025, impacting publicly traded companies including Golden Entertainment and AbbVie.Some support3 reports1 development inside
-
Medicare eligibility rules affect AbbVie drug pricing, while the FDA regulates Creon's classification and approval for Medicare beneficiaries.Some support1 report1 development inside
-
AbbVie and Cerevel Therapeutics successfully launched a new drug for Parkinson's disease, pending government coverage negotiations.Some support3 reports
-
A fund holding diverse stocks, including Canadian dividend stocks, was mentioned as part of its strategy.Some support1 report
-
Johnson & Johnson, JPMorgan Chase, and AbbVie are dividend payers in the VYM fund.Some support1 report
-
AbbVie and Boehringer Ingelheim are engaging with financial advisory firms regarding potential deals and discussing M&A strategies in the competitive pharmaceutical market.Some support1 report
-
Pete Sessions sold shares of Apple Inc. and AbbVie, with the transactions disclosed via SEC filings.Some support1 report
-
Lost patent protection for Humira in the US on August 20, 2025.Well supported11 reports
-
Pharmaceutical companies are producing testosterone replacement therapies, which are being touted as anti-aging treatments, while the U.S. military tests service members' levels.Some support2 reports1 development inside
-
AbbVie and Cisco are noted as large-cap holdings in the market.Some support1 report
-
AbbVie, Abbott Laboratories, and Johnson & Johnson were recommended as dividend stocks for retirees, operating in the healthcare sector.Some support2 reports1 development inside
-
Multiple major pharmaceutical companies were identified as industry peers for growth during a capital markets day.Some support1 report1 development inside
-
AbbVie, AstraZeneca, and Bristol-Myers Squibb collaborated on the AISB Bind AI initiative.Some support2 reports
-
Iambic Therapeutics announced multiple new partnerships, including collaborations with Jazz Pharmaceuticals and AbbVie, and received backing from Qatar Investment Authority and Nvidia.Well supported4 reports
One to three months ago
-
AbbVie announces support for a scholarship program across Canada, coinciding with Josh Berman's leadership role in Crohn's and Colitis Canada.Some support1 report
-
Biosimilar erosion is impacting market share, and AbbVie, Procter & Gamble, and Johnson & Johnson are noted as major consumer goods players.Some support2 reports
-
Julien Perrier previously held senior roles at both AbbVie and Sanofi.Some support1 report
-
Syndax Pharmaceuticals and AbbVie are competing in the healthcare and biopharma sector.Some support2 reports
-
Norges Bank purchased a new position in AbbVie stock, leading to a required institutional holdings disclosure filed with the SEC on July 2, 2026.Well supported5 reports
-
Millennium Management increased its stake in AbbVie and purchased shares of SpaceX stock on September 12, 2026.Some support3 reports
-
HSBC raised its price target to $315, and the FDA issued a complete response letter regarding trenibotE.Some support1 report
-
AbbVie and Novo Nordisk are high-profile pharmaceutical stocks serving over 45 million people worldwide, with Cor acting as a significant distribution partner.Some support1 report
-
Morgan Stanley reaffirmed an overweight rating on AbbVie, and Barclays raised its price objective on September 10, 2026.Some support1 report
-
AbbVie executives outlined growth plans at a conference hosted by Wells Fargo.Some support1 report
-
Millennium Management increased its stakes in AbbVie and Costco, and Israel Englander founded the firm.Some support2 reports
-
AbbVie, AstraZeneca, and GSK are major players in global drug development, facing challenges in the drug class and pursuing licensing deals with Chinese biotechs.Some support1 report2 developments inside
-
Pharmaceutical companies, including AbbVie and GSK, funded studies comparing drug spending, with Michael Johnson discussing Australia vs. New Zealand spending.Some support1 report
-
AbbVie and Johnson & Johnson are top exposures in the VYM ETF, which itself holds Microsoft.Some support5 reports
-
The FDA reviewed gene therapy applications and provided milestone payments for dosing involving Regenxbio and AbbVie.Some support1 report1 development inside
-
AbbVie is listed on the Nasdaq stock exchange, and MarketBeat is reporting on its stock performance.Some support1 report
-
Companies including AbbVie, Verizon, Philip Morris International, and Southern Company were selected for dividend income.Some support2 reports
-
Citigroup and Royal Bank of Canada raised price targets and ratings for a company, with MarketBeat aggregating the financial data.Some support4 reports
-
AbbVie submitted an application for the Skyrizi induction regimen to the European Medicines Agency.Some support2 reports
-
Moderna, Merck, and AbbVie are seeking new revenue streams to offset losses caused by patent expirations.Some support2 reports
No events began in the chosen period. Widen it, or reset.
What's reaching AbbVie
Events traced to AbbVie, step by step, newest first- Local elections may influence AbbVie's investment incentivesLocal elections may influence AbbVie's investment incentives in Durham CountyPossible
- Regulatory streamlining may increase competition for AbbVie's biologicsAbbVie may face increased competition as regulatory streamlining lowers market barriersPossible
- Medicare exemption may boost AbbVie's revenue potentialMedicare exemption may boost AbbVie's revenue potentialLikely
- AbbVie may benefit from capital shift into healthcare sectorAbbVie may benefit from capital shift into healthcare sectorPossible
- Nxera Pharma's APAC expansion may influence AbbVie collaboration termsNxera Pharma's APAC expansion may influence AbbVie collaboration termsPossible
Explainers that pass through AbbVie
AbbVie is a step on the way to someone else- JNJ and AbbVie co-commercialization intensifies competition for Eli LillyIncreased competition from JNJ and AbbVie may challenge Eli Lilly's market share.Possible
- JNJ and AbbVie's IMBRUVICA deal may increase pressure on PfizerIncreased competition from JNJ and AbbVie may pressure Pfizer's market share.Possible
Around AbbVie this week
News at the entities that move AbbVie most-
Securities and Exchange Commission StructuralCitigroup reaffirmed an outperform rating on Barrett Business Services, Inc. while the SEC mandated 13F filings for investment disclosures.Moves AbbVie
-
Halozyme Therapeutics StructuralCorcept Therapeutics and Halozyme Therapeutics are identified as top holdings in specific U.S. small-cap ETFs.Moves AbbVie
-
FDA StructuralTraceLink advances multinational compliance roadmaps in Egypt and Ethiopia while addressing FDA's transition to 12-digit National Drug Code.Moves AbbVie
-
Health Canada StructuralNeighboring provinces are monitoring Chronic Wasting Disease (CWD) and Health Canada is advising on human risk.Moves AbbVie
-
Donald Trump OperationalSergey Lavrov met in Bahrain and criticized the US plan for the Gaza Strip, while Trump's proposals for Gaza remain unfulfilled.Moves AbbVie
-
Medicare StructuralTrump campaigned against Kamala Harris' healthcare plans, while Harris previously supported Medicare for All.Moves AbbVie
Connections
The 40 strongest of 506, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Genmab Structural
AbbVie and Genmab maintain a formal partnership for joint drug development, clinical trials, and commercialization, including profit-sharing.
-
Cerevel Therapeutics Structural
AbbVie successfully acquired Cerevel Therapeutics for $8.7 billion, integrating its technology into the larger entity.
-
Research Triangle Transactional
AbbVie plans a $1.4B investment in the Research Triangle region.
-
Securities and Exchange Commission Structural
AbbVie is subject to mandatory financial disclosure and reporting requirements enforced by the Securities and Exchange Commission.
-
Robert A. Michael Structural
Robert A. Michael serves as the CEO of AbbVie.
-
AstraZeneca Operational
AbbVie and AstraZeneca are direct competitors in oncology and dyslipidemia, while also engaging in strategic collaborations, such as AI initiatives.
-
HUMIRA Structural
AbbVie's corporate strategy and financial health are structurally defined by the lifecycle and subsequent decline of its legacy drug, Humira, due to patent expiration and biosimilar competition.
-
Halozyme Therapeutics Structural
AbbVie utilizes proprietary ENHANZE technology licensed from Halozyme Therapeutics.
Show all 40 connections
-
Eli Lilly and Company Operational
AbbVie and Eli Lilly are direct competitors in the pharmaceutical market, vying for market share and therapeutic dominance.
-
FDA Structural
The FDA formally regulates and grants market approvals and designations for AbbVie's pharmaceutical products.
-
Health Canada Structural
Health Canada formally regulates and approves products and operations of AbbVie.
-
MarketBeat Mentioned together
MarketBeat tracks, rates, and reports on AbbVie's stock performance and financial data.
-
Pfizer Operational
AbbVie and Pfizer are direct competitors in the pharmaceutical industry, vying for market share and investment capital.
-
Donald Trump Operational
Donald Trump exerts operational influence on AbbVie through regulatory threats regarding drug prices and direct stock purchases.
-
Bristol-Myers Squibb Operational
The companies are active pharmaceutical peers engaged in market competition and collaborative research initiatives.
-
Cantor Fitzgerald Operational
Cantor Fitzgerald provides financial ratings, price targets, and market commentary on AbbVie shares.
-
Johnson & Johnson Operational
AbbVie and Johnson & Johnson are direct competitors in the biopharmaceutical sector, vying for market share in oncology and immunology.
-
Cencora Structural
AbbVie utilizes Cencora as a wholesale partner to distribute a concentrated portion of its U.S. sales market.
-
Amgen Operational
AbbVie and Amgen are direct competitors and peers within the biopharmaceutical sector, particularly in the psoriatic arthritis market.
-
Medicare Structural
AbbVie's market access, pricing, and launch success are structurally dependent on Medicare's coverage and negotiation decisions.
-
European Commission Structural
The European Commission formally evaluates and grants market authorization for AbbVie's pharmaceutical products in the European market.
-
SEC Structural
AbbVie must comply with SEC regulations regarding institutional investment activity and stock holdings disclosure.
-
Norges Bank Transactional
Norges Bank has repeatedly invested in and acquired stakes in AbbVie shares.
-
Royalty Pharma Structural
Royalty Pharma holds ongoing royalty rights to AbbVie's products, generating revenue from AbbVie's sales.
-
Enanta Pharmaceuticals (United States) Structural
AbbVie commercializes products developed by Enanta, providing Enanta with royalty revenue and funding its operations.
-
Sanofi Operational
The companies are actively competing in the pharmaceutical market, evidenced by direct product rivalry and shared M&A pursuit.
-
ReGenX Biosciences (United States) Operational
AbbVie and ReGenX Biosciences maintain an ongoing operational partnership focused on joint drug development and clinical trials.
-
Morgan Stanley Mentioned together
Morgan Stanley provides financial ratings and price targets based on analysis of AbbVie's stock and growth prospects.
-
Kori Wallace Structural
Kori Wallace holds the position of Vice President at AbbVie.
-
Citadel Transactional
Citadel has significantly increased its financial stake in AbbVie shares through share purchases.
-
Galderma Operational
The two companies are direct competitors in the market for injectables, specifically pitting Galderma's products against AbbVie's Botox.
-
Pharmacyclics Structural
AbbVie owns Pharmacyclics, establishing a parent-subsidiary relationship.
-
Food and Drug Administration Structural
AbbVie relies on the FDA for regulatory review, designation, and market approval of its products.
-
Gilgamesh Pharmaceuticals Transactional
AbbVie has repeatedly acquired drug programs and candidates from Gilgamesh Pharmaceuticals.
-
European Medicines Agency Structural
The European Medicines Agency reviews and grants market approval for AbbVie's pharmaceutical products in Europe.
-
Biogen Operational
AbbVie and Biogen are identified as direct competitors and peers operating in the biotechnology and neuroscience markets.
-
Guggenheim Partners Transactional
AbbVie engages with Guggenheim Partners in a transactional capacity regarding corporate deals and financial matters.
-
Moderna Operational
AbbVie and Moderna are major competitors operating within the high-risk biotechnology and pharmaceutical sectors.
-
Ken Griffin Transactional
Ken Griffin's fund has repeatedly purchased or increased its investment stake in AbbVie.
-
Sarah Cannon Research Institute Operational
AbbVie and Sarah Cannon Research Institute are engaged in strategic alliances and clinical trials for cancer therapy innovations.
History
Events by the month they beganOctober 2026
13 events- AbbVie presented clinical data at the European Society for Medical Oncology (ESMO) Congress held in Madrid.
- Ken Griffin made investment moves on October 18, 2026, buying shares of AbbVie and Abbott Laboratories, and boosting Eli Lilly shares.
- AbbVie presented research findings related to Inflammatory Bowel Disease (IBD) at the United European Gastroenterology (UEG) Week conference.
- AbbVie overcame the loss of Humira exclusivity, leading to a stock rally while Pfizer stock sank.
- Johnson & Johnson is co-commercializing the prescription medicine IMBRUVICA with Pharmacyclics, a subsidiary of AbbVie.
- AbbVie presented abstracts at the American College of Gastroenterology meeting.
- Major pharmaceutical companies are competing for investment capital.
- AbbVie, Boehringer Ingelheim, and Pfizer were present at a clinical conference in Las Vegas.
- Jay Korada held senior analytics roles at both AbbVie and Bristol-Myers Squibb.
- Canandaigua National Trust Co of Florida bought a new stake in AbbVie shares and granted Breakthrough Therapy Designations for one of its drugs.
- OpenSecrets tracked donations to Virginia Foxx, who held stocks in AbbVie, in North Carolina.
- Analysts highlighted bullish calls and raised price targets for AbbVie, Moderna, and Eli Lilly amid sector optimism.
- AbbVie, Amgen, Micron Technology, and NetApp all showed strength in the stock market on October 7, 2026.
September 2026
24 events- AbbVie and Cerevel Therapeutics successfully launched a new drug for Parkinson's disease, pending government coverage negotiations.
- A fund holding diverse stocks, including Canadian dividend stocks, was mentioned as part of its strategy.
- Johnson & Johnson, JPMorgan Chase, and AbbVie are dividend payers in the VYM fund.
- AbbVie and Boehringer Ingelheim are engaging with financial advisory firms regarding potential deals and discussing M&A strategies in the competitive pharmaceutical market.
- Pete Sessions sold shares of Apple Inc. and AbbVie, with the transactions disclosed via SEC filings.
- AbbVie and Cisco are noted as large-cap holdings in the market.
- Multiple major pharmaceutical companies were identified as industry peers for growth during a capital markets day.
- AbbVie, AstraZeneca, and Bristol-Myers Squibb collaborated on the AISB Bind AI initiative.
- Iambic Therapeutics announced multiple new partnerships, including collaborations with Jazz Pharmaceuticals and AbbVie, and received backing from Qatar Investment Authority and Nvidia.
- AbbVie announces support for a scholarship program across Canada, coinciding with Josh Berman's leadership role in Crohn's and Colitis Canada.
- Biosimilar erosion is impacting market share, and AbbVie, Procter & Gamble, and Johnson & Johnson are noted as major consumer goods players.
- Julien Perrier previously held senior roles at both AbbVie and Sanofi.
- Syndax Pharmaceuticals and AbbVie are competing in the healthcare and biopharma sector.
- Millennium Management increased its stake in AbbVie and purchased shares of SpaceX stock on September 12, 2026.
- HSBC raised its price target to $315, and the FDA issued a complete response letter regarding trenibotE.
- AbbVie and Novo Nordisk are high-profile pharmaceutical stocks serving over 45 million people worldwide, with Cor acting as a significant distribution partner.
- Morgan Stanley reaffirmed an overweight rating on AbbVie, and Barclays raised its price objective on September 10, 2026.
- AbbVie executives outlined growth plans at a conference hosted by Wells Fargo.
- Millennium Management increased its stakes in AbbVie and Costco, and Israel Englander founded the firm.
- AbbVie, AstraZeneca, and GSK are major players in global drug development, facing challenges in the drug class and pursuing licensing deals with Chinese biotechs.
- Pharmaceutical companies, including AbbVie and GSK, funded studies comparing drug spending, with Michael Johnson discussing Australia vs. New Zealand spending.
- AbbVie and Johnson & Johnson are top exposures in the VYM ETF, which itself holds Microsoft.
- AbbVie is listed on the Nasdaq stock exchange, and MarketBeat is reporting on its stock performance.
- Companies including AbbVie, Verizon, Philip Morris International, and Southern Company were selected for dividend income.
August 2026
7 events- Financial results and stock performance comparisons among AbbVie, Johnson & Johnson, Eli Lilly, and Merck.
- AbbVie, Altria, and CVX are being utilized in a dividend ladder investment strategy.
- Medicare eligibility rules affect AbbVie drug pricing, while the FDA regulates Creon's classification and approval for Medicare beneficiaries.
- The FDA reviewed gene therapy applications and provided milestone payments for dosing involving Regenxbio and AbbVie.
- Citigroup and Royal Bank of Canada raised price targets and ratings for a company, with MarketBeat aggregating the financial data.
- AbbVie submitted an application for the Skyrizi induction regimen to the European Medicines Agency.
- Moderna, Merck, and AbbVie are seeking new revenue streams to offset losses caused by patent expirations.
Show 2 earlier months
July 2026
2 events- Pharmaceutical companies are producing testosterone replacement therapies, which are being touted as anti-aging treatments, while the U.S. military tests service members' levels.
- Norges Bank purchased a new position in AbbVie stock, leading to a required institutional holdings disclosure filed with the SEC on July 2, 2026.
June 2026
14 events- Kori Wallace was appointed vice president at AbbVie.
- AbbVie's Humira is losing exclusivity and facing intense competition from Skyrizi and Rinvoq.
- AbbVie products are succeeding Humira in the market, while FDA approvals and Fed caution influence market expectations.
- A group of major pharmaceutical companies, including AbbVie, Bristol-Myers Squibb, Amgen, Pfizer, Moderna, and Merck, are noted as peers operating in the highly regulated pharmaceutical sector.
- Declining sales of Humira due to biosimilar erosion.
- AbbVie and Eli Lilly are competing in the pharmaceutical market.
- Medicare pricing negotiations are impacting major pharmaceutical companies, including AbbVie, Eli Lilly, and Merck, who are seeking pricing exemptions.
- AbbVie, Genmab, and Sarah Cannon Research Institute announced the joint development of Epkinly for DLBCL treatment.
- A drug application from AbbVie is currently seeking a positive opinion from the CHMP, with the final decision impacting market access in the EU.
- MarketBeat's screener has identified a list of dividend stocks.
- AbbVie's product portfolio was bolstered by the acquisition of Allergan, while Humira sales faced erosion due to patent loss and biosimilar competition.
- A tariff plan caused market tanking on August 22, 2025, impacting publicly traded companies including Golden Entertainment and AbbVie.
- Lost patent protection for Humira in the US on August 20, 2025.
- AbbVie, Abbott Laboratories, and Johnson & Johnson were recommended as dividend stocks for retirees, operating in the healthcare sector.